Editor, Rebekah Jordan, sat down with Dr. Gen Li, president and co-founder of Phesi, to learn more about how the company’s AI-driven clinical database is allowing insights and observations to be drawn from big clinical trial data.
EPM conducted a roundtable with several pharma experts to learn what pharma industry trends to watch out for in 2023, from AI drug discovery through to the rise of decentralised trials.
With AI becoming more prevalent in the pharma space, Raman Bhatnagar, Pharmaceuticals lead, Aspen Technology, explores the power of machine learning and analytics, and how this helps anticipate failure prediction in pharma manufacturing.
Shafique Virani, chief corporate development officer and interim chief medical officer, Recursion, delves into digital transformation within drug discovery and the power of AI-enabled platforms in the future of therapeutics.
Abbie Fisher, associate at European Intellectual Property Firm, Withers & Rogers, discusses patenting a new frontier in personalised medicine with AI-powered biomarker discovery.
Rebekah Jordan talks with Peter Shone, chief technology officer, iethico, about its latest AI-powered platform that can give clear indications of medicine shortages and predict future supply chain challenges - and what this means for pharmacists.
Jason Smith, CTO, AI & Analytics, Within3, describes the possibilities made by AI in supporting the life sciences sector, and how it can allow pharma experts to produce real time results and yield better insights.
Ari Goldfarb, CEO, Kando, discusses how innovative technologies and artificial intelligence tools are advancing wastewater analysis and could potentially mitigate the effects, or even prevent, future pandemics.
Withers & Rogers gives an insight into the new ways that AI is helping to accelerate drug discovery and highlights the challenges that exist when bringing such innovations to market.
We know disease exists, where it comes from and how it evolves - but we don’t yet know ahead of time when something changes to mark the start of a new disease, a new variant or just an increase in transmission.
Oliver Schacht, CEO of OpGen looks at why technologies including artificial intelligence and machine learning could be key to combatting antimicrobial resistance.
Ray Chohan co-founder and vice president of new ventures at innovation intelligence expert Patsnap looks at technology’s ability to expedite the analysis of data in pharma and how it can help bring about new therapies for patients.
